ScinoPharm in API Supply Pact
ScinoPharm, a Taiwan-based contract provider of active pharmaceutical ingredient (API) manufacturing services, has formed a supply pact with Melinta Therapeutics, a New Haven, Connecticut-based biopharmaceutical company.
ScinoPharm will provide commercial manufacturing from its facility in Tainan, Taiwan of delafloxacin, the API in Melinta’s Baxdela, a drug for treating acute bacterial skin and skin structure infections. In June 2017, the US Food and Drug Administration approved Baxdela (delafloxacin) for treating acute bacterial skin and skin structure infections caused by susceptible bacteria. Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathogens, including MRSA (methicillin-resistant Staphylococcus aureus).